Abingworth — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)Jeet Mahal(Executive Officer, Director)Patrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Board seatKurt von Emster· per SEC Form D · $132M raise · filed Aug 2026
Co-investorsAvego BioScience CapitalTSVCIkarian Capital
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Board seatBali Muralidhar· per SEC Form D · $315M raise · filed Jul 2026
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAlly Bridge Group+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.